drugset / Trial / NCT05637281

Clinical Efficacy of Indomethacin in Early Treatment of Acute Pancreatitis

NCT05637281

RandomizedParallel-groupOpen-labelTreatment

Summary

Acute pancreatitis is a common critical disease of the digestive system. Accumulated data showed that overexpression of cyclooxygenase-2 (COX-2) in acute pancreatitis and experimental pancreatitis could be attenuated with COX-2 inhibitors. In recent years, it has been found that timely administration of indomethacin or diclofenac sodium to anus after ERCP can significantly reduce the incidence of AP after ERCP in patients at high risk of AP. The aim of this study was to evaluate the efficacy of rectal indomethacin in reducing the systemic inflammatory response syndrome (SIRS) score in AP patients.

Timeline

Start
2022-12-11
Primary completion
2023-12-11
Completion
2023-12-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Indomethacin Small molecule 50 mg Rectal